Altre lingue Kancera AB

Azioni

KAN

SE0015658570

Tempo differito Nasdaq Stockholm Altri mercati azionari 11:52:05 02/05/2024			Variaz. 5gg	Var. 1 gen.
1,46 ^SEK	-0,68%		-2,41%	-67,88%

23/02	Kancera AB (publ) riporta i risultati degli utili per l'intero anno terminato il 31 dicembre 2023	CI
23/02	Kancera AB (Publ) firma un accordo di licenza con l'Università di Newcastle	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Kancera announces the outcome of the company's rights issue	20/03
Kancera publishes prospectus in connection with the company’s rights issue	01/03
Kancera resolves on a rights issue of approximately SEK 121.9 million	23/02
Interim Report Fourth Quarter 2023, October 1 – December 31 Kancera AB (publ.), org.no. 556806-8851	23/02
Kancera signs license agreement and obtains global commercial rights to the results from the FRACTAL study	23/02
Kancera AB Reports Earnings Results for the Full Year Ended December 31, 2023	23/02
Kancera AB Signs A License Agreement with the University of Newcastle	23/02
Kancera AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	23/02
Kancera presents the statistical analysis of top line data from the FRACTAL study	06/02
Kancera AB Presents the statistical Analysis of Top Line Data from the FRACTAL Study	06/02
Kancera reports positive top line results from the FRACTAL study	20/12
Kancera AB Reports Positive Top Line Results from the FRACTAL Study	20/12
Kancera provides operational update in connection with release of financial interim report for third quarter 2023	17/11
Interim Report Third Quarter July 1 – September 30, 2023 Kancera AB (publ.), org.no. 556806-8851	17/11
Kancera AB Provides Operational Update Regarding Fractalkine Block Blockers KAN567 and KAND145	17/11
Kancera AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	17/11
Kancera reports that the phase I study of KAND145 has received regulatory approval	23/10/23
Kancera AB Receives Finnish Regulatory Agency Approval for Phase I Study of KAND145	23/10/23
Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023	13/10/23
Kancera Names Successor to Outgoing Chief Medical Officer	01/09/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Kancera AB

Azioni

KAN

SE0015658570

Altre lingue

Filtri